Bluebird, a Cambridge, Mass.-based biotech company, prices its rare autosomal recessive disorder treatment for $2.8 million and another gene therapy drug for $3 million. Both medications are intended for one-time use, but because the pool of potential customers is small, the price tag may not be enough to keep the drugmaker in business.
“Do I think those sorts of prices are in the right ballpark for a one-time curative therapy for something like this?” Stuart Arbuckle, chief operating officer of Vertex Pharmaceuticals, which is developing a sickle-cell disease drug, told Bloomberg. “Yeah, I think those are in the right ballpark.”
Vertex told Bloomberg that Mr. Arbuckle’s comments should not be read as a hint toward the price of its genetic therapy drug, which has not been released. But the Institute for Clinical and Economic Review seems to agree with this “ballpark” figure.
In July, the ICER said Zynteglo, Bluebird’s $2.8 million treatment for beta thalassemia, which affects 1 in 100,000 people, should cost $2.1 million “given the high costs of standard care.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
